Search - tctmd.com

Displaying 281 - 300 of 671

Sort: Relevancy | Date

Presentation

BRIGHT: Bivalirudin vs Heparin With or Without Tirofiban During Primary PCI in Acute MI

Presenter: Yaling Han

March 23, 2015

Presentation

Mortality in Pts Treated With Extended Duration Dual Antiplatelet Therapy (DAPT) After DES

Presenter: T. Palmerini

March 18, 2015

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Presentation

Atheroma Progression in Hyporesponders to Statin Therapy

Presenter: Y. Kataoka

March 11, 2015

Presentation

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Presenter: Martine Gilard

March 10, 2015

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

Presentation CADECI 2015

Importancia De La Terapia Combinada Bajo Las Nuevas Guías Para El Manejo De La Hipertensión Arterial

Presenter: Dr. Enrique G?mez ?lvarez

February 20, 2015

Presentation CADECI 2015

El tratamiento Antiplaquetario Actual en el Síndrome Coronario Agudo ¿Es retornar al Futuro?

Presenter: Dr. Marco Antonio Ramos Corrales

February 20, 2015

Presentation

Association Between the Use of Fondaparinux vs LMWH and Clinical Outcomes in NSTEMI Patients

Presenter: Karolina Szummer

February 19, 2015

Presentation

Prognostic Impact of Clopidogrel Pretreatment in Patients With ACS Managed Invasively

Presenter: Manuel Almendro-Delia

February 05, 2015

Presentation

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Presenter: Patricia A. Cowper

February 02, 2015

Presentation

Conflicting Results Between RCTs and Observational Studies on the Impact of PPIs on Cardiovascular Events When Coadministered With DAPT

Presenter: Chiara Melloni

January 25, 2015

Presentation

Effect of a Shortened Duration Eptifibatide Infusion (75 mg) as Adjunctive Therapy for PCI

Presenter: Scott D. Nei

January 15, 2015

Presentation

Bivalirudin vs Heparin With or Without GPIs in Patients With STEMI Undergoing Primary PCI

Presenter: Gregg W. Stone

January 05, 2015

Presentation

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Presenter: Gregg W. Stone

December 01, 2014

Presentation

Anticoagulant Therapy During Primary PCI for AMI

Presenter: Sripal Bangalore

November 13, 2014

Presentation

SECURITY: Second-Generation DES Implantation Followed by 6- vs 12-Month DAPT

Presenter: Antonio Colombo

November 10, 2014

Presentation Cardiovascular Interventions 2014

How to Manage Post PCI Antiplatelet Therapy in the Patient on Oral Anticoagulation

Presenter: David P. Faxon

October 23, 2014

Presentation

VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel

Presenter: J.M. Cubero

October 06, 2014

Presentation

Impact of Diabetes and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients with Stable CAD Receiving DES

Presenter: Laurent Feldman

October 06, 2014

Advertisement

BRIGHT: Bivalirudin vs Heparin With or Without Tirofiban During Primary PCI in Acute MI

Mortality in Pts Treated With Extended Duration Dual Antiplatelet Therapy (DAPT) After DES

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Atheroma Progression in Hyporesponders to Statin Therapy

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Importancia De La Terapia Combinada Bajo Las Nuevas Guías Para El Manejo De La Hipertensión Arterial

El tratamiento Antiplaquetario Actual en el Síndrome Coronario Agudo ¿Es retornar al Futuro?

Association Between the Use of Fondaparinux vs LMWH and Clinical Outcomes in NSTEMI Patients

Prognostic Impact of Clopidogrel Pretreatment in Patients With ACS Managed Invasively

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Conflicting Results Between RCTs and Observational Studies on the Impact of PPIs on Cardiovascular Events When Coadministered With DAPT

Effect of a Shortened Duration Eptifibatide Infusion (75 mg) as Adjunctive Therapy for PCI

Bivalirudin vs Heparin With or Without GPIs in Patients With STEMI Undergoing Primary PCI

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Anticoagulant Therapy During Primary PCI for AMI

SECURITY: Second-Generation DES Implantation Followed by 6- vs 12-Month DAPT

How to Manage Post PCI Antiplatelet Therapy in the Patient on Oral Anticoagulation

VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel

Impact of Diabetes and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients with Stable CAD Receiving DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content